Randomized Evaluation of Radotinib Versus Imatinib in Phase III Study for Efficacy With Chinese Patients (RERISE China)
A Phase III, Multi-center, Open-Label, Randomized Study of the Efficacy of Radotinib Versus Imatinib in Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myeloid Leukemia Chinese Patients in Chronic Phase
Sponsor: Il-Yang Pharm. Co., Ltd.
Listed as NCT03722420, this PHASE3 trial focuses on Chronic Myeloid Leukemia, Chronic Phase and remains ongoing. Sponsored by Il-Yang Pharm. Co., Ltd., it has been updated 13 times since 2018, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
13 versions recorded-
Nov 2024 — Present [monthly]
Active Not Recruiting PHASE3
-
Sep 2024 — Nov 2024 [monthly]
Active Not Recruiting PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Active Not Recruiting PHASE3
-
Apr 2024 — Jul 2024 [monthly]
Active Not Recruiting PHASE3
-
Oct 2023 — Apr 2024 [monthly]
Active Not Recruiting PHASE3
▶ Show 8 earlier versions
-
Jan 2022 — Oct 2023 [monthly]
Active Not Recruiting PHASE3
Status: Recruiting → Active Not Recruiting
-
Jan 2021 — Jan 2022 [monthly]
Recruiting PHASE3
-
Mar 2020 — Jan 2021 [monthly]
Recruiting PHASE3
-
Nov 2019 — Mar 2020 [monthly]
Recruiting PHASE3
-
Sep 2019 — Nov 2019 [monthly]
Recruiting PHASE3
-
Mar 2019 — Sep 2019 [monthly]
Recruiting PHASE3
Status: Not Yet Recruiting → Recruiting
-
Dec 2018 — Mar 2019 [monthly]
Not Yet Recruiting PHASE3
-
Nov 2018 — Dec 2018 [monthly]
Not Yet Recruiting PHASE3
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Il-Yang Pharm. Co., Ltd.
For direct contact, visit the study record on ClinicalTrials.gov .